英国におけるChAdOx1 nCoV-19の第2回または第3回投与後の反応性および免疫性: 2つのランダム化対照試験 (COV001およびCOV002) のサブ研究
PubMedで要約を見る
まとめ
この要約は機械生成です。COVID-19 ワクチン (ChAdOx1 nCoV-19) の投与間隔を延長すると,抗体反応が強化されます. 3回目のワクチンは抗体とT細胞の免疫をさらに強化し,保護の改善を示しています.
科学分野
- * 免疫学とワクチン学
- * 感染症 疫学
- * 臨床試験と翻訳研究
背景
- *世界的なCOVID-19ワクチンの供給不足により,投与間隔の延長を評価する必要がある.
- * 遅延された第2用量と第3用ブースターを含む様々な予防接種戦略が世界中で検討されています.
- * ChAdOx1 nCoV-19 (AZD1222) の免疫原性を評価することは,ワクチンの有効性を最適化するために極めて重要です.
研究 の 目的
- * ChAdOx1 nCoV-19 の単一投与後の免疫の持続性を評価する.
- * 第1回と第2回ChAdOx1 nCoV-19投与の間の延長された間隔 (44 - 45週間) の後の免疫性評価.
- * 3回目の ChAdOx1 nCoV-19 投与に対する免疫反応を決定する.
主な方法
- * ChAdOx1 nCoV-19試験の第1・2期 (COV001) と第2・3期 (COV002) のボランティア (18~55歳) のサブスタディ.
- 2回目 (44~45週間) と3回目 (2~38週間) の再投与の反応性および免疫性データの分析
- * 44~45週までの標準の2回投与と1回投与の受験者との比較
主要な成果
- * ChAdOx1 nCoV-19 の単回投与後,抗体タイターは44~45週間の間,基値より有意に高かった.
- * 投与間隔が長かった (44〜45週間) の結果,抗体位数が短かった (8〜12週間または15〜25週間) よりも高かった.
- * 第3回投与では,抗体の位数が大幅に増加し,T細胞の反応が増加し,反応性も第1回投与より低かった.
結論
- * 2回目の ChAdOx1 nCoV-19 投与の間隔を延長すると,抗体反応が強化されます.
- * 3 度目の ChAdOx1 nCoV-19 投与は,抗体レベルとT細胞の反応を効果的に高める.
- * 免疫保護を最適化するために,柔軟なChAdOx1 nCoV-19ワクチン接種スケジュールをサポートしています.
関連する概念動画
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Overview
The ability of a single antibody to recognize multiple structurally similar epitopes is an important immune defense strategy that enables the host to efficiently defend against many potentially threatening pathogens. However, cross-reactivity also elicits allergy symptoms against related allergens. It is increasingly important to understand the principles of cross-reactivity, as antibodies are actively being developed as therapeutic modalities for diverse diseases, including cancer.
Overview
Vaccination is the administration of antigenic material from pathogens to confer immunity against a specific microorganism. Vaccination primes the immune system to recognize and mount an immune response faster and more effectively if the real pathogen is encountered. Vaccinations are one of the most efficient ways to protect both individual humans and the general public from disease. A growing anti-vaccination skepticism risks the successes of vaccination programs that helped reduce...
Overview
We speak of an allergy when the immune system triggers a response against a benign foreign structure, like food, pollen or pet dander. These elicitors are called allergens. If the immune system of a hypersensitive individual was primed against a specific allergen, it will trigger allergic symptoms during every subsequent encounter of the allergen. Symptoms can be mild, such as hay fever, to severe, such as potentially fatal anaphylactic shock.
Sensitization Is the First Step of an...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

